Ophthalmic and Physiological Optics, Journal Year: 2024, Volume and Issue: 44(3), P. 674 - 677
Published: March 1, 2024
Language: Английский
JAMA Ophthalmology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 23, 2025
This Viewpoint discusses the ophthalmic device, red light therapy, for myopia treatment in children and adolescents China, including its development use, safety concerns, implications surrounding recent regulatory changes reclassification of this device.
Language: Английский
Citations
0
JAMA Ophthalmology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 24, 2025
This Viewpoint examines results from the LIGHTSIDE trials for photobiomodulation to treat age-related macular degeneration and raises questions regarding trial protocols efficacy safety of therapy.
Language: Английский
Citations
0
Eye and Vision, Journal Year: 2025, Volume and Issue: 12(1)
Published: March 5, 2025
To evaluate myopia control efficacy in myopic children wearing spectacle lenses with highly aspherical lenslets (HAL) for 5 years. This is a randomized, double-masked extended trial. Myopic aged 8 to 13 years who were originally allocated the HAL group 2-year clinical The underwent 5-year assessment progression using cycloplegic spherical equivalent refraction (SER) and axial length (AL). An extrapolated single-vision (ESVL) was used as group. elongation of ESVL calculated based on data from same trial, following 3 estimated by assuming an annual reduction SER 9.7% AL 15%. A generalized linear model approach treatment efficacy. validity evaluated comparing first year 3-year estimates (SVL2) 1-year study Forty-three participants original completed visit (74%). Five-year [mean ± standard error (SE)] - 1.27 0.14 D. Compared (- 3.03 0.18 D), 1.75 0.24 D less (P < 0.001). mean over 0.67 0.06 mm compared 1.40 0.001), slower 0.72 0.10 No significant differences found 0.58 0.04 vs. 0.56 0.05 D) or (0.28 0.02 0.28 mm) between SVL2 (PSER = 0.83; PAL 0.93) 3. In this study, spectacles reduced rate elongation, preventing elongation. Long-term use also decreased incidence high myopia. Extrapolated groups are valid evaluating long-term studies. Trial registration registered at Chinese Clinical Registry (ChiCTR2100047262), https://www.chictr.org.cn/showproj.html?proj=127182 .
Language: Английский
Citations
0
Graefe s Archive for Clinical and Experimental Ophthalmology, Journal Year: 2025, Volume and Issue: unknown
Published: March 19, 2025
Language: Английский
Citations
0
Ophthalmic and Physiological Optics, Journal Year: 2025, Volume and Issue: unknown
Published: April 11, 2025
Language: Английский
Citations
0
Acta Ophthalmologica, Journal Year: 2025, Volume and Issue: unknown
Published: April 11, 2025
To determine the effectiveness of various interventions in reducing myopia progression children. Literature databases were searched on December 2, 2023: PubMed, Embase, Cochrane Central, Web Science Core Collection, BIOSIS Previews, Current Contents Connect, Data Citation Index, Derwent Innovations KCI-Korean Journal Database, Preprint ProQuest™ Dissertations and Theses Index SciELO Index. PRISMA guidelines Handbook recommendations followed. All unique analyzed individually order to generate clinically applicable results. The main outcome was axial length progression. Secondary outcomes incident corneal infiltrates, photophobia, development an allergic response towards intervention, visual acuity at near distance drop-out from allocated intervention/control. We identified 74 RCTs involving 12 154 participants aged 6-18 years. Network meta-analysis compared after 1 year between 45 placebo or single-vision spectacles. most effective reported weighted mean difference 95% confidence interval low-level red-light (-0.33 mm (-0.40, -0.25)), ortho-K with 5 treatment zone (-0.32 (-0.41, -0.24)), aspheric base curve (-0.29 (-0.37, -0.22)), atropine 1.0% (-0.28 (-0.30, -0.26)), combined 0.01% (-0.24 -0.11)), spectacles highly aspherical lenslets (-0.23 (-0.26, -0.19)), increased compression factor (-0.28, -0.17), 0.05% (-0.21 -0.13)) defocus incorporated multiple segments (-0.27, -0.15)). Photophobia reduced near-visual for atropine, lower adherence found 1.0%. There no significant association any infiltrates reactions. Over 70% studies conducted Asian populations. This systematic review network highlights efficacy interventions, including orthokeratology lenses, slowing elongation Low-level therapy also slowed progression, but further research is needed assess potential side effects. Future should include diverse populations standardized methodologies enhance applicability comparability
Language: Английский
Citations
0
Ophthalmic and Physiological Optics, Journal Year: 2025, Volume and Issue: unknown
Published: April 22, 2025
Abstract In this paper, three key questions regarding our understanding of myopia are addressed: predictors onset, the mechanism underlying its development and potential treatments to slow progression. To explore these aspects, first, a non‐invasive biomarker using chicken model was investigated. A strong correlation found between both increased ultraviolet (UV) fundus reflectivity thinning retinal nerve fibre layer (RNFL). Through electron microscopy, it observed that, within hours vision deprivation, significant myelin sheaths around large axons in RNFL occurred, accompanied by an increase UV reflectivity—changes that took place even before eye elongation. These findings suggest early degradation contributes may serve as predictive animal model. However, prediction onset humans remains challenging. investigate further, visual stimuli affecting emmetropic myopic eyes differently were examined. The results indicated have weaker responses positive defocus short‐term stimulation simulated chromatic aberrations when compared with eyes, suggesting possible impairment signalling pathways responsible for detecting blur defocus. terms treatment, reading text inverted contrast (bright letters on dark background) induced axial length shortening choroidal thickening eyes. Furthermore, repeated exposure digitally shown reduce thickness effectively human subjects. align from models indicate approach strategy control. more research is necessary establish effective control intervention suitable children adolescents.
Language: Английский
Citations
0
JAMA Ophthalmology, Journal Year: 2025, Volume and Issue: unknown
Published: April 24, 2025
Importance Repeated low-level red light (RLRL) therapy has emerged as a potential intervention for controlling myopia progression in children. However, its long-term effects on retinal photoreceptors remain relatively unknown. Objective To evaluate changes associated with RLRL cone photoreceptor density children using high-resolution adaptive optics scanning laser ophthalmoscopy (AOSLO). Design, Setting, and Participants This retrospective multicenter cohort study analyzed data collected from January to March 2024, focusing Chinese myopia. All participants were recruited through questionnaires. Cone measurements obtained AOSLO images. Children aged 5 14 years the pediatric ophthalmology clinic during routine eye examinations included assigned group or control group. Inclusion criteria spherical equivalent refraction below −6.00 diopters (D) best-corrected visual acuity ≥20/20. Exposures measurement Main Outcomes Measures was measured along 4 meridians central fovea 4° eccentricity AOSLO. Fundus abnormalities assessed AOSLO, optical coherence tomography (OCT), fundus photography. Image evaluators masked allocation. Results A total of 99 this analysis: 52 (97 eyes; mean [SD] age, 10.3 [1.9] years; 27 female [51.9%]) 47 (74 9.8 [2.1] 25 male [53.2%]) users showed decreased within 0.5-mm foveal center, most notably temporal region. At 0.3-mm eccentricity, difference −2.1 × 10 3 cells/mm 2 compared controls (95% CI, −3.68 −0.59 ; P = .003). 11 eyes exhibited abnormal low-frequency, high-brightness signals near fovea. The odds ratio nonusers 7.23 1.15-303.45; Fisher exact test, .02). One participant had small cystoid OCT ganglion cell layer, which resolved months after discontinuing therapy. Conclusions Relevance suggest that at least 1 year reduced paracentral other subtle some receiving control. These findings support need further research longer-term safety similar individuals.
Language: Английский
Citations
0
Ophthalmic and Physiological Optics, Journal Year: 2024, Volume and Issue: 44(3), P. 672 - 673
Published: March 1, 2024
Paul Cooke, the CEO of Eyerising International, an Australian company that is legal manufacturer a Repeated Low-Level Red-Light device, would appreciate opportunity to address some points regarding article, 'Red light instruments for myopia exceed safety limits'.1 The authors wrote: 'Of note, and New Vision used in clinical trials, claims Class 1 do not appear be supported by their published measurement data'. We dispute this statement. does 'claim' designation; it 'has' Group instrument classification, indicating no potential hazard exists, as defined American National Standards Institute (ANSI) Z80.36-2021 standard. standard which US Food Drug Administration (FDA) currently require International every other manufacturers ophthalmic meet. In conclusion, article 'Instrument must take into account ANSI standards lasers applications ensure retina at risk photochemical damage'. But they themselves did use latest standards. They stated Z136.1 benchmark tests. acknowledged were developed protect individuals from hazardous exposures occupational situations, guidelines subsequently added Z136 2008. Since then, have established specifically instruments. Z80.36 specifies fundamental requirements optical radiation It applies all (including current, new emerging instruments) direct into, or at, eye. also those parts therapeutic surgical systems eye diagnostic, illumination, measurement, imaging alignment purposes.2 was later standard, instruments, FDA required meet we obtained. Therefore, imply device misleading. 'In based on measurements our laboratory, recommended clinicians strongly reconsider low level red (LLRL) therapy children until can confirmed'. several issues with First, only two devices tested laboratory neither them so question why frequently refer article. Third, basing conclusions tests different ignored Myopia Management Device's proven record both trial real-world settings. has undergone 10 trials four studies, covering 1785 patients, cumulative 9.25 years—with zero significant adverse events being recorded. been treat more than 160,000 patients real world over past 8 years, there are 80,000 daily users. To date, five cases side effects reported, permanent damage referenced case study 12-year-old girl China who experienced event, without mentioning patient had followed device. fact, continued weeks after first experiencing prolonged afterimages, contrary 'Instructions Use' (IFU) issued Nor report follow-up found fully recovered. As 21 December 2022, 4 months discontinuing RLRL, patient's cornea appeared clear retinal structure intact. corrected visual acuity eyes recovered 0.8 decimal equivalent (6/7.5). OCT showed integrity continuity ellipsoid zone macular restored.3 takes responsibility ensuring efficacy RLRL seriously. remain committed working closely healthcare professionals users collect investigate any reactions concerns. market entered, asked relevant authorities what certification then successfully obtained certification; subsequently, regulatory approval. United States, met told needed certified meeting submitted ANSI-approved testing facility given classification. therefore reject suggestion fails applicable standards.1 Both risks benefits should evaluated treatments, important acknowledge treatments carry inherent risks. However, numerous international having conducted analyses approved it, concluded far outweigh John Battersby: Writing – original draft (equal); writing review editing (equal). author communications specialist engaged assist framing response.
Language: Английский
Citations
2
Ophthalmic and Physiological Optics, Journal Year: 2024, Volume and Issue: 45(1), P. 160 - 176
Published: Nov. 12, 2024
Abstract Purpose To summarise pooled estimates of the efficacies various myopia control interventions, as drawn from published meta‐analyses. Method PubMed, SCOPUS and Web Science were searched inception to February 2024 for systematic reviews meta‐analyses reporting treatment effects strategies. The qualities included assessed using 16‐item A MeaSurement Tool Assess Reviews ( AMSTAR ) 2. An intervention was defined having a clinically significant effect if it resulted in change spherical equivalent refraction (SER) ≥0.50 D/year or axial length (AL) ≤−0.18 mm/year. Results total 38 studies identified. overall respective changes SER AL, mean difference (95% CI) high‐concentration (≥0.5%) atropine 0.67 D (0.58–0.77) −0.24 mm (−0.36 −0.11); moderate‐concentration (>0.05% <0.5%) 0.48 (0.34–0.62) −0.23 (−0.27 −0.19); low‐concentration (0.01%, 0.025%, 0.05%) 0.33 (0.23–0.43) −0.14 (−0.19 −0.09); orthokeratology −0.47 (−0.66 −0.28); peripheral plus soft contact lenses 0.30 (0.18–0.42) −0.35 (−0.62 −0.08); spectacles 0.77 (0.40–1.14) −0.43 (−0.78 multifocal 0.21 (0.11–0.31); repeated low‐level red light therapy 0.55 (0.46–0.65) −0.25 (−0.29 −0.20); outdoor time 0.17 (0.16–0.18) −0.04 (−0.06 −0.01). Conclusion High moderate concentrations atropine, orthokeratology, demonstrated on slowing AL elongation, while high progression.
Language: Английский
Citations
2